Adial Pharmaceuticals, Inc.
NCM: ADILLive Quote
About Adial Pharmaceuticals, Inc.
Healthcare
Biotechnology
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
📊 Fundamental Analysis
Adial Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -170.7%, which indicates that capital utilization is currently under pressure.
At a current price of $1.57, ADIL currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $1.54 - $30.25).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$4.74M
Trailing P/E
--
Forward P/E
-0.33
Beta (5Y)
1.40
52W High
$30.25
52W Low
$1.54
Avg Volume
94K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App